Main Health News Today
Bristol study finds Covid booster gives tenfold increase in antibodies
NHS racism shame: One in three Black and minority ethnic staff face...
Stricter rules for tattoos and piercings in Wales
FDA puts limit on lead levels in baby food
Study finds heightened cancer death risk in patients with type 2 diabetes
Posterior Microsurgical Instruments Market Business Strategy, Price and Gross...
2023-01-25 09:52:50

Thousands of migraine sufferers could benefit from drug on NHS

Logo The Independent
The Independent
By Jane Kirby

Thousands of people who suffer from migraines could benefit from a drug that has been approved on the NHS.

The National Institute for Health and Care Excellence (Nice) said it was recommending eptinezumab (also called Vyepti) for preventing migraine in around 164,000 adults where at least three previous preventive treatments have failed.

The drug is taken in hospital every 12 weeks as an intravenous infusion and works to stave off migraines.

Nice said medical opinion suggests eptinezumab would be reserved for people with severe migraine attacks or who may be unable to take other jabs at home.

Continue read on independent.co.uk

Related Posts
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:12:00
Initiation of the Phase 3 study for the second long-acting injectable antipsychotic using MedinCell's tec
The Phase 3 study conducted in the U.S. will assess the efficacy and safety of the first subcutaneous long-acting Injectable (LAI) formulation of olanzapine...
Logo GlobeNewswire
SciencePress Release2023-01-25 09:00:00
VPM oversees clinical trial and translational project management Positive Phase I data of client Memo Therapeutics AG
HANNOVER, Germany, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Vakzine Projekt Management GmbH (VPM), a German drug development consultancy and service provider...
Logo Nasdaq
Business / FinanceBy Rtt News2023-01-23 13:22:13
Blueprint Medicines: FDA Grants Priority Review For Supplemental New Drug Application For AYVAKIT
(RTTNews) - Blueprint Medicines Corporation (BPMC) announced the FDA has accepted the company's supplemental new drug application for AYVAKIT for the...
Logo Benzinga
Business / FinanceBy Pr Newswire2023-01-24 17:14:00
Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assign
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Avadel Pharmaceuticals Announces Publication of Real-World DataHighlighting the Risk of Accidental Dosing Errors with...
- Adverse events were reported in patients who took the second, middle-of-the-night dose of immediate-release oxybate less than 2.5 hours after the first...
Logo EIN Presswire
HealthPress Release2023-01-24 10:58:20
Epidural Anesthesia Disposable Devices Market Huge Growth in Future Scope 2023-2030 | B. Braun, Becton, Teleflex.
Epidural Anesthesia Disposable Devices Epidural anesthesia offers analgesia or reduces pain rather than providing an anesthetic effect. BURLINGAME,...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Baudax Bio Announces Positive Outcome of Interim Analysis of Phase II Randomized Trial for BX1000
MALVERN, Pa., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company focused on innovative products for hospital and...
Logo PR Newswire
TechnologyPress Release2023-01-24 19:12:00
HIGH-COST PRESCRIPTION RELIEF
Pay as little as $0 for your prescriptions TROY, N.Y. and PHILADELPHIA, Jan. 24, 2023 /PRNewswire/ -- Health Insurance Solutions Inc. (HISI) and Levrx...
Logo CNBC
Business / FinanceBy Spencer Kimball2023-01-24 13:36:05
The FDA's power to approve drugs faces sweeping challenge in lawsuit seeking to pull abortion pill from U.S. market
Key Points Anti-abortion physicians are suing to overturn the FDA's approval of mifepristone, which dates back more than two decades. Mifepristone used in...
Logo EIN Presswire
HealthPress Release2023-01-24 10:48:12
Childhood Absence Epilepsy Treatment Market Growth in Future Scope 2023-2030 | Cavion, Inc., Pfizer, Inc.
Childhood Absence Epilepsy Treatment Market Absence seizures (previously known as petit-mal) are commonly found in children than in adults with frequent...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Aspargo Receives Regulatory Approval to Market Sildenafil Spray in Germany, Ireland, and The Netherlands
The aggregate German, Irish and Dutch market for erectile dysfunction (ED) market exceeds $175 million Aspargo plans to launch Sildenafil Spray in Germany,...
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 18:09:00
VITRAC Therapeutics Initiates a Phase 1 Clinical Trial with the Aurora Kinase A Inhibitor VIC-1911 and G1
VITRAC Therapeutics, LLC (VITRAC) initiated a Phase 1 Study of VIC-1911 as monotherapy and in combination with sotorasib for the treatment of KRAS G12C...
Logo GlobeNewswire
SciencePress Release2023-01-24 12:30:00
Verrica Pharmaceuticals Announces Resubmission of New Drug Applicationfor VP-102 for the Treatment of Molluscum...
Potential First FDA-approved Therapy for Treatment of Molluscum Contagiosum Prevalence of Over 6 Million Molluscum Contagiosum Patients in the U.S. Alone...
Logo PR Newswire
HealthPress Release2023-01-23 13:00:00
Blueprint Medicines Announces FDA Acceptance of Supplemental New Drug Application for AYVAKIT® (avapritinib) for the...
-- FDA grants priority review and sets PDUFA action date of May 22, 2023 -- CAMBRIDGE, Mass., Jan. 23, 2023 /PRNewswire/ -- Blueprint Medicines Corporation...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:17:00
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
HAMILTON, BERMUDA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant...
Logo GlobeNewswire
SciencePress Release2023-01-24 13:00:00
Cerevance to Participate at the SVB Global Biopharma Conference
BOSTON, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS)...
Logo GlobeNewswire
SciencePress Release2023-01-24 12:00:00
Tonix Pharmaceuticals Announces Publication of Paper in Antiviral Research Highlighting the Companys Development of...
Data Represent Research and Development Work Being Conducted at Tonixs Infectious Disease R&D Center (RDC) in Frederick, Md. CHATHAM, N.J., Jan. 24, 2023...
Logo PR Newswire
HealthPress Release2023-01-24 17:14:00
Fabre-Kramer Pharmaceuticals Announces FDA Acceptance of NDA Resubmission as Complete Response and Assignment of...
Submission of EXXUA (gepirone HCl), a novel targeted single serotonin receptor agonist for treatment of Major Depressive Disorder receives PDUFA action date...
Logo PR Newswire
HealthPress Release2023-01-24 13:05:00
icotec ag Receives FDA Clearance for the Ø 4.5mm VADER® Pedicle Screws
ALTSTAETTEN, Switzerland, Jan. 24, 2023 /PRNewswire/ -- icotec ag, the leading medical device manufacturer of Carbon/PEEK spinal implants, announces the U.S....
Logo Benzinga
Business / FinanceBy Business Wire2023-01-24 22:46:00
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferre
Verastem Oncology VSTM, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a...